SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors scrutinize its AI strategy ahead of the upcoming Worldwide Developers Conference, where a long-awaited Siri overhaul and integration with Google's Gemini are expected to take center stage. Community sentiment is deeply polarized, with many users debating whether the companys AI efforts are genuine innovation or a lagging "sell the news" event, while traders closely monitor the stock's elevated valuation and its role as a potential defensive anchor in the broader tech market.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is currently driving significant community engagement as investors shift focus toward its transition from Bitcoin mining to becoming a major AI and high-performance computing infrastructure provider. While the stock continues to experience volatility, discussions are heavily centered on the potential of the Helios data center project and hopes for upcoming tenant announcements to serve as a catalyst for growth.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is experiencing significant momentum driven by a 92% objective response rate in a pancreatic cancer trial combining vopimetostat and daraxonrasib. The community is actively discussing the potential for a short squeeze due to high short interest, while analysts remain bullish on the company's precision oncology pipeline.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is trending as investors digest a massive $400 million convertible note offering while speculating on an imminent data center partnership with a major hyperscaler like Amazon Web Services. Despite recent volatility and broader market selling, the community remains intensely focused on the company's progress at its Moses Lake facility and the potential for a transformative lease agreement to drive institutional re-rating.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors debate whether the stock is a deep-value opportunity supported by aggressive share buybacks and potential AI-driven cost savings, or a value trap struggling against stiff competition. Community sentiment is deeply polarized, with many frustrated by the persistent downward price action, while others advocate for long-term accumulation based on strong free cash flow and recent international integration news.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors digest the recent submission of a key patent for Orange Book listing, which aims to extend exclusivity for its flagship drug Miplyffa through 2041. The community is actively debating the potential impact of this intellectual property milestone on long-term market protection, while also monitoring upcoming analyst price target adjustments and broader speculation regarding a potential buyout as the company matures.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors rotate capital out of software and mega-cap tech, with the community actively debating whether the decline is driven by broader market manipulation, concerns over aggressive AI capital spending, or a shift in sentiment toward other sectors. The conversation remains highly polarized, featuring a mix of traders looking to reload on positions at key technical levels and skeptics questioning the stock's recent performance compared to other market leaders.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is attracting significant attention following its multi-billion dollar collaboration with Roche to co-develop the blood cancer drug bexobrutideg. The community is actively debating the deal's impact on Nurix's valuation and long-term potential, with many investors focusing on the substantial upfront payment and the validation this partnership provides for their proprietary protein degradation technology.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing downward pressure as investors rotate capital toward upcoming major IPOs and react to broader tech-sector concerns regarding sustained, high-level AI infrastructure spending. Community sentiment remains split, with many analysts and long-term investors viewing current pullbacks as a strategic buying opportunity due to AWS's cloud dominance, while others express frustration over recent price volatility and high capital expenditure.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is gaining momentum as investors anticipate the federal rescheduling of cannabis, with community discussions centering on the company's strong profitability, active share buybacks, and its potential as a primary candidate for a major exchange uplisting. Traders are closely tracking upcoming earnings and institutional accumulation, viewing current price levels as a strategic entry point ahead of anticipated industry-wide regulatory shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VIR trying 2 re-enter 8.57 250 now b a .60 x .61 6/8 11:07 am EDT 
PREVIOUS PROFIT TAKING 
 
05/22/2026  
Sell 
 
VIR VIR BIOTECHNOLOGY INC 300 $9.14 $0.12 $2,741.88 More 
05/21/2026  
Buy 
 
VIR VIR BIOTECHNOLOGY INC 300 $9.05  -$2,715.00

StockTwits Web

Vir Biotechnology Inc

 trying 2 re-enter 8.57 250 now b a .60 x .61 6/8 11:07 am EDT 
PREVIOUS PROFIT TAKING 
 
05/22/2026  
Sell 
 
VIR VIR BIOTECHNOLOGY INC 300 $9.14 $0.12 $2,741.88 More 
05/21/2026  
Buy 
 
VIR VIR BIOTECHNOLOGY INC 300 $9.05  -$2,715.00